A Multicenter Randomized Bioequivalence Study of a Novel Ready-to-Use Temozolomide Oral Suspension vs. Temozolomide Capsules

• Váldodahkkit: François Ducray (Dahkki), Carole Ramirez (Dahkki), Marie Robert (Dahkki), Maxime Fontanilles (Dahkki), Charlotte Bronnimann (Dahkki), Olivier Chinot (Dahkki), Florian Estrade (Dahkki), Xavier Durando (Dahkki), Stéphanie Cartalat (Dahkki), Jeremy Bastid (Dahkki), Hugues Bienayme (Dahkki), Caroline Lemarchand (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: MDPI AG, 2023-11-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Background: Temozolomide (TMZ) oral suspension (Ped-TMZ, KIZFIZO^®) is being developed for the treatment of relapsed or refractory neuroblastoma, a rare cancer affecting infants and young children. The study assessed the safety and the bioequivalence of this novel pediatric for...